From: Impact of SGLT2 inhibitors on patient outcomes: a network meta-analysis
Population | Outcome | Empagliflozin | Dapagliflozin | Canagliflozin | Sotagliflozin | Ertugliflozin | TSA |
---|---|---|---|---|---|---|---|
DM | Death | Lowest risk | Lower risk | Lower risk | Without significance | Without significance | Non-conclusion |
CV death | Without significance | Lowest risk | Without significance | Without significance | Without significance | Non-conclusion | |
CV death or HHF | Lower risk | Lower risk | Lower risk | Lower risk | Without significance | Conclusion* | |
Kidney function progression | Lower risk | Lowest risk | Lower risk | Without significance | Without significance | Conclusion* | |
AKI | Lower risk | Lower risk | Lower risk without significance | Without significance | Without significance | Conclusion* | |
Ketoacidosis | Without significance | Without significance | Higher risk without significance | Without significance | Higher risk without significance | Â | |
Lower limb amputation | Without significance | Without significance | Highest risk | Without significance | Higher risk without significance | Â | |
UTI | Without significance | Without significance | Higher risk without significance | Without significance | Highest risk | Â | |
Mycotic genital infections | Higher risk | Highest risk | Higher risk | Higher risk | Higher risk | Â | |
Hypoglycemia | Without significance | Lower risk without significance | Without significance | Without significance | Without significance | Â | |
Bone fracture | Without significance | Without significance | Higher risk without significance | Without significance | Without significance | Â | |
Non-DM | Death | Higher risk than Dapagliflozin without significant difference | Lower risk | NR | NR | NR | Non-conclusion |
CV death | Lower risk | Lower risk | NR | NR | NR | Non-conclusion | |
CV death or HHF | Lower risk | Lower risk | NR | NR | NR | Conclusion* | |
Kidney function progression | Lower risk | Lower risk | NR | NR | NR | Conclusion* | |
AKI | Lower risk | Lower risk | NR | NR | NR | Conclusion* | |
Lower limbs amputation | Without significance | Without significance | NR | NR | NR | Â | |
HF | MACEs | Â | Without significance | Lower risk without significance | Lowest risk | Without significance | Non-conclusion |
CV death or HHF | Lower risk | Lower risk | Without significance | Lowest risk | Without significance | Conclusion* | |
Non-HF | MACEs | Â | Lower risk without significance | Lowest risk | Â | Without significance | Non-conclusion |
CV death or HHF | Lower risk | Lower risk | Lowest risk | Â | Without significance | Non-conclusion | |
CKD | Kidney-specific composite outcome | Lowest risk | Lower risk | Lower risk | Â | Â | Â |
CV death or HHF | Lower risk | Lowest risk | Â | Â | Â | Conclusion* | |
Renal-specific composite outcome | Lowest risk | Â | Lower risk without significance | Â | Â | Â | |
Non-CKD | Kidney- specific composite outcome | Lowest risk | Â | Â | Â | Â | Â |
CV death or HHF | Lowest risk | Â | Lower risk | Â | Â | Conclusion* |